FDA Clears Welireg and Lenvima Combination for Advanced Clear Cell Kidney Cancer After Immunotherapy

The US Food and Drug Administration has approved a new all-oral treatment combination for adults with advanced kidney cancer whose disease has already been treated with PD-1 or PD-L1 immunotherapy. The regimen combines Welireg with Lenvima for renal cell carcinoma containing a clear cell component.

The decision provides another treatment option for patients whose cancer has progressed after immune checkpoint therapy. It is also the first FDA-approved regimen to combine an HIF-2 alpha inhibitor with a VEGFR-targeted tyrosine kinase inhibitor in this setting.

What Supported the Approval

The approval is based on the Phase 3 LITESPARK-011 trial, which compared Welireg plus Lenvima with Cabometyx in 747 adults with locally advanced or metastatic clear cell renal cell carcinoma that had progressed after PD-1 or PD-L1 inhibitor therapy.

At a preplanned interim review, Welireg plus Lenvima lowered the risk of disease progression or death by 26% compared with Cabometyx. Median progression-free survival was 14.6 months with the combination versus 10.6 months with Cabometyx.

The combination also produced a higher objective response rate. Tumors shrank by a predefined amount in 53% of patients who received Welireg plus Lenvima, compared with 40% of those treated with Cabometyx.

Overall survival did not meet the trial's predefined requirement for statistical significance. At the final analysis, median overall survival was 33.7 months with Welireg plus Lenvima and 28.6 months with Cabometyx.

That result indicates a favorable numerical trend but does not establish a statistically confirmed survival advantage. The FDA approval relies on the statistically significant progression-free survival and tumor-response improvements.

How WELIREG acts?

Welireg blocks HIF-2 alpha, targeting a central pathway in clear cell kidney cancer. Lenvima inhibits several receptor tyrosine kinases, including VEGF receptors that contribute to tumor blood-vessel growth. Together, the medicines target both tumor-cell hypoxia signaling and the vascular system tumors use to grow.

This differs from Cabometyx, which is a multi-targeted kinase inhibitor but does not directly inhibit HIF-2 alpha.